Search Results - "Liszkay, G."

1113 Distance between primary melanoma site and the brain strongly affects brain metastasis-free survival, head-neck location as the main predictor for early onset of brain metastases by Gorka, E, Czirbesz, K, Fabo, D, Liszkay, G

Get full text

Aquaporin-1 Protein Expression of the Primary Tumor May Predict Cerebral Progression of Cutaneous Melanoma by Imrédi, E., Liszkay, G., Kenessey, I., Plotár, V., Gödény, M., Tóth, B., Fedorcsák, I., Tímár, József

“…Brain metastasis is a frequent complication of the progression of malignant melanoma. In a previous study aquaporin 1 (AQP1) protein expression was found to be…”
Get full text

524 Tumor-infiltrating immune cells as potential biomarkers predicting response to treatment and survival in patients with metastatic melanoma receiving ipilimumab therapy by Ladányi, A, Sebestyén, T, Balatoni, T, Varga, A, Oláh, J, Liszkay, G

Get full text

P.2.b.011 Low-dose interferon-alpha induced depression is significantly alleviated by social support in melanoma patients: potential biological explanations by Kovacs, P, Panczel, G, Balatoni, T, Liszkay, G, Gonda, X, Bagdy, G, Juhasz, G

Get full text

25LBA Impact of baseline genetic heterogeneities on progression-free survival (PFS) in patients (pts) with advanced BRAFV600-mutated melanoma treated with cobimetinib (COBI) + vemurafenib (VEM) in the phase 3 coBRIM study by McArthur, G, Larkin, J, Dréno, B, Ascierto, P, Liszkay, G, Maio, M, Mandal´, M, Demidov, L, Stroyakovskiy, D, Thomas, L, De la Cruz-Merino, L, Atkinson, V, Dutriaux, C, Garbe, C, Wongchenko, M, Hsu, J, Koralek, D, Rooney, I, Yan, Y, Ribas, A

Get full text

9325 POSTER Prognostic Impact of B-Cell Infiltration in Melanoma by Ladanvi, A, Kiss, J, Mohos, A, Somlai, B, Liszkay, G, Gilde, K, Fejos, Z, Gaudi, I, Timár, J

Get full text

1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma by Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., di Pietro, A., Ascierto, P.A.

Get full text

813P Time to development of central nervous system (CNS) metastases (mets) with atezolizumab (A) or placebo (P) combined with vemurafenib (V) + cobimetinib (C): Updated results from the phase III IMspire150 study by Lewis, K., Robert, C., Ramella Munhoz, R., Liszkay, G., de la Cruz Merino, L., Olah, J., Queirolo, P., Mackiewicz, J., Li, H., Zhu, Q., Hertig, C., Paranthaman, N., McKenna, E.F., Gutzmer, R., McArthur, G., Ascierto, P.A.

Get full text

786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma by Dummer, R., Pathan, N., Deng, S., Robert, C., Arance Fernandez, A.M., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., di Pietro, A., Xie, T., Ascierto, P.A., Flaherty, K.

Get full text

602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma by Haydon, A.M., Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., Di Pietro, A., Ascierto, P.A.

Get full text

Serum concentration of 5-S-cysteinyldopa in patients with melanoma by Bánfalvi, T., Gilde, K., Boldizsár, M., Fejös, Z., Horváth, B., Liszkay, G., Beczássy, E., Kremmer, T.

“…Background 5‐S‐cysteinyldopa (5‐S‐DC) is a precursor of melanin. Its serum and urinary level can reflect melanoma progression. In this study we examined the…”
Get full text

1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma by Dummer, R., Flaherty, K.T., Robert, C., Arance, A., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsová, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., Zohren, F., Edwards, M., Ascierto, P.A.

Get full text

Malignant melanomas of the urogenital tract by Szabó, B.F, Szű, M, Szé, E, Pánczé, G, Liszkay, G, Nyirády, P

Get full text

1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS by Robert, C., Flaherty, K.T., Gogas, H.J., Fernandez, A.M. Arance, Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., de Groot, J.W.B., Dutriaux, C., Loquai, C., Harney, A., Kiprilov, E., Pickard, M.D., Cantey-Kiser, J., Dummer, R., Ascierto, P.A.

Get full text

1137P Incidence and time course of adverse events (AEs) with atezolizumab (A) in combination with vemurafenib (V) and cobimetinib (C) in the phase III IMspire150 study by Lewis, K., Robert, C., Ascierto, P.A., Munhoz, R., Liszkay, G., Merino, L. de la Cruz, Olah, J., Queirolo, P., Mackiewicz, J., Li, H., Zhu, Q., McKenna, E., McNally, V., Gutzmer, R., McArthur, G.

Get full text

PCN67 - Retrospective Comparison Of Real-Life Survival Data From Single Centre Trials - The Clinical Outcome Of Vemurafenib Therapy In Metastatic Melanoma Patients by Porneczy, E, Czirbesz, K, Toth, E, Liszkay, G, Boncz, I

Get full text

Retrospective Comparison Of Real-Life Survival Data From Single Centre Trials - The Clinical Outcome Of Vemurafenib Therapy In Metastatic Melanoma Patients by Porneczy, E, Czirbesz, K, Toth, E, Liszkay, G, Boncz, I

Get full text

PCN40 Healthcare Resource Utilization in Patients Treated with Encorafenib PLUS Binimetinib for BRAF-Mutant Metastatic Melanoma: DATA from Columbus, a Phase 3 Trial in BRAF-Mutant Melanoma by Mandala, M., Arance, A., Dummer, R., Ascierto, P.A., Gogas, H., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., Loquai, C., Tadmouri, A., Pickard, M.D., Gollerkeri, A., Robert, C., Flaherty, K.T.

Get full text

Hospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma by Arance, A., Dummer, R., Ascierto, P.A., Gogas, H., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., de Parseval, L.A., Pickard, M., Sandor, V., Robert, C., Flaherty, K.T.

Get full text

Quality-of-life (QoL) in COLUMBUS part 1: A phase 3 trial of encorafenib (ENCO) plus binimetinib (BINI) versus vemurafenib (VEM) or ENCO in braf-mutant melanoma by Gogas, H., Dummer, R., Ascierto, P.A., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsová, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., de Parseval, L.A., Pickard, M., Sandor, V., Robert, C., Flaherty, K.T.

Get full text